Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul>
<li>Futura Medical specialises in the development and commercialisation of innovative sexual health products.</li>
<li>The lead product is Eroxon, which is a clinically proven treatment for erectile dysfunction.</li>
<li>In November 2025, £2.75m was raised at 1p and the shares are down from a 52 week high of 34p. </li>
</ul>


Futura Medical specialises in the development and commercialisation of innovative sexual health products.
The lead product is Eroxon, which is a clinically proven treatment for erectile dysfunction.
In November 2025, £2.75m was raised at 1p and the shares are down from a 52 week high of 34p. 


United Kingdom

Futura Medical plc develops pharmaceutical and medical devices for sexual health. The Company is developing products to help men maintain erections and women to maintain lubrication during intercourse.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Futura Medical (FUM LN)

Friday Take Away: 21 November 2025

Futura Medical specialises in the development and commercialisation of innovative sexual health products. The lead product is Eroxon, which is a...

Hybridan

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)